On the heels of EDC’s 2017 U.K. trade mission, San Diego-based Edico Genome and Genomics England announced a new partnership to strengthen the accuracy and consistency of next-generation sequencing (NGS) data analysis in Genomics England’s Rare Disease Pilot. The partnership will support Genomics England in making NGS the standard of care across the U.K.’s National Health Service in 2018.
Specifically, the partnership will focus on the analysis pipeline − improving alignment and variant calling of whole-genome sequencing data. Genomics England selected DRAGEN for its industry leading accuracy and speed, enabling the organization to accelerate analysis of large clinical genomic datasets.